VANCOUVER, B.C. – BC Cancer scientists, in partnership with the University of British Columbia, Memorial Sloan Kettering Cancer Center (MSK) and Microsoft, have developed a new method for analyzing cancer tissue, allowing them to learn more about cancer than previously possible. Researchers can now read the genomes of single cells within a tumour, opening up a new wave of understanding of how and why cancer develops and changes over time.
This new method is so sensitive that researchers will now be able to analyze single cells from a tissue, and decode their genomes individually. This is a key element to understanding cell evolution – including how normal, seemingly healthy cells become cancerous and why cancerous cells spread and become resistant to treatment over time. The method will unlock the answers to crucial questions like: the origins of cancer, why cancers evolve, why do they become resistant to drugs and why do they metastasize. This research will also be a key pathway to cancer prevention, understanding the root environmental causes of the disease.
“The ways in which the cells differ from each other turns out to be important for understanding why they stop responding to treatments,” says Dr. Samuel Aparicio, BC Cancer distinguished scientist, a professor in UBC’s faculty of medicine, and co-lead author on the study with Dr. Sohrab Shah, BC Cancer scientist, associate professor in UBC’s faculty of medicine and current Chief of Computational Oncology at Memorial Sloan Kettering. “It also tells us something about the history of the cancer; how it developed, how long it’s been inside healthy tissue, and how long it’s been growing. In some cases, a pattern of mutation in the genome might tell us that that person has been exposed to a carcinogen or some other thing in the environment which predisposes to that cancer. That’s what the methodology brings - the ability to address all of those questions.”
The new approach brings together leading-edge methods in genomics and computer science from the laboratories of Dr. Aparicio and Dr. Shah.
This advance comes nearly a decade after Dr. Aparicio and Dr. Shah and their team’s first foundational shift in decoding cancer: the ability to sequence human cancer genomes, which opened up a new era in understanding cancer and has since been transformational in the field. The team began with two genomes, in a 2009 landmark study of cancer metastasis in a breast cancer and today has decoded more than 500,000 single cell cancer genomes, 50,000 of which are released into the public domain through this study. In the last ten years, cancer genomics findings have sparked new drug treatments, new ways of diagnosing cancer and new ways of monitoring cancer.
“Basic and translational research is essential to advancing medical discoveries that will have a profound impact on patient care,” says Dr. François Bénard, vice president, research, BC Cancer. “We are proud of the work our researchers do and the collaboration between partners including the University of British Columbia and Memorial Sloan Kettering.”
“A new era of cancer research and care is here, and we are so grateful to our donors who have supported Dr. Aparicio and his team at BC Cancer for the past decade, bringing hope and promise to patients in B.C.,” says Sarah Roth, president & CEO, BC Cancer Foundation.
“Sometimes obtaining the knowledge takes a bit of time and persistence, but there’s a message of hope in here,” says Aparicio. “Over the next ten years, we anticipate this technology will enable a fundamentally improved understanding of cancer biology leading to better ways to target cancers, predict response to therapy and combine interventions to improve the lives of patients.”
“We’re excited to be able to present this technology to other scientists, both at MSK and beyond,” adds Dr. Shah.
Research teams in the United Kingdom and United States have already begun to adopt the methodology developed at BC Cancer in Vancouver.
, a program of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visit bccancer.bc.ca
or follow us on Twitter @BCCancer
The BC Cancer Foundation is the fundraising partner of BC Cancer. Together with our donors we are changing the outcome for people affected by cancer in B.C. and beyond by connecting personalized care, innovative research and opportunities to contribute. We are the largest funder of cancer in B.C. and every dollar raised stays right here at BC Cancer to advance research, enhance care and break down cancer to benefit the people of B.C.
The University of British Columbia
is a global centre for research and teaching, consistently ranked among the top 20 public universities in the world. Since 1915, UBC’s entrepreneurial spirit has embraced innovation and challenged the status quo. UBC encourages its students, staff and faculty to challenge convention, lead discovery and explore new ways of learning. At UBC, bold thinking is given a place to develop into ideas that can change the world. For more information, visit ubc.ca
or follow us on Twitter @UBC
For media enquiries, please contact:
Senior Specialist, Marketing & Communications, BC Cancer Foundation